Painting protein misfolding in the cell in real time with an atomic-scale brush

The direct observation of specific biochemical events in living cells is now possible as a result of combined advances in molecular biology and fluorescence microscopy. By genetically encoding the source of a unique spectroscopic signal, target proteins can be selectively detected within the complex cellular environment, with limited interference from background signals. A recent study takes advantage of arsenical reagent-based methodologies to monitor in vivo protein misfolding and inclusion body formation in real time. This approach promises to yield important information on the kinetics of aggregate formation in living cells and its relation to the time-course of protein expression and post-translational processing. The ability to follow protein self-association in real time accurately from its early stages is unique to this method, and has far-reaching implications for both biotechnology and misfolding-based disease.

Recent Advances in Small Molecule Microarrays: Applications and Technology

The field of Small Molecule Microarray's (SMM's) is an ever-expanding part of the larger microarray field. SMM's are array based detection systems that use small molecules as probes immobilized on a variety of microarray surfaces that are screened against a number of targets for purposes including, but not limited to, protein-small molecule ligand recognition and protein function profiling. This review covers the recent advances in the field with particular emphasis on the successful applications of SMM's, as well as technical advances in platform optimization and novel small molecule immobilization strategies.

Carbohydrate microarrays - a new set of technologies at the frontiers of glycomics

Carbohydrate microarray technologies are new developments at the frontiers of glycomics. Results of 'proof of concept' experiments with carbohydrate-binding proteins of the immune system - antibodies, selectins, a cytokine and a chemokine - and several plant lectins indicate that microarrays of carbohydrates (glycoconjugates, oligosaccharides and monosaccharides) will greatly facilitate not only surveys of proteins for carbohydrate-binding activities but also elucidation of their ligands. It is predicted that both naturally occurring and synthetic carbohydrates will be required for the fabrication of microarrays that are sufficiently comprehensive and representative of entire glycomes. New leads to biological pathways that involve carbohydrate-protein interactions and new therapeutic targets are among biomedically important outcomes anticipated from applications of carbohydrate microarrays.

Working with Xenopus spinal neurons in live cell culture

Neurons from the Xenopus spinal cord are highly versatile and easily manipulated, making them an ideal model system to answer questions regarding the cellular and molecular basis of early neural development and function. Xenopus has been a productive model system in studies ranging from axon growth and guidance to synaptic plasticity. Exogenous molecules, such as proteins, fluorescent tracers, and nucleic acids, can be injected into early blastomeres to load tracers in all neurons or into late blastomeres to target specific classes of neurons based on established lineage maps. Xenopus spinal neurons also provide an excellent culture system, as neurons extend processes on a variety of substrata and develop at room temperature in minimal salt solutions. Live fluorescent neurons can be imaged for hours with fluorescence microscopy at room temperature in static cultures without neurotrophic support or serum. This highly reduced culture system minimizes variables that can confound interpretation of results. Cultures can be prepared at various stages of development as dissociated neurons or as spinal cord explants. Both excitatory and inhibitory neurons develop in culture, and synaptic contacts among neurons and between neurons and nonneuronal targets form naturally. The simple anatomy and rapid rostral-to-caudal development of the Xenopus spinal cord also make this an excellent in vivo model system to analyze axon guidance by identifiable classes of neurons. This chapter focuses on techniques that exploit both in vitro and in vivo qualities of this system.

Clinical molecular imaging

This review summarizes the rapidly growing field of molecular imaging, the spatially localized and/or temporally resolved sensing of molecular and cellular processes in vivo. Molecular imaging is used to map the anatomic locations of specific molecules of interest within living tissue and has enormous potential as a powerful means to diagnose and monitor disease. Molecular imaging agents comprise a targeting component that confers localization and a component that enables external detectability with an imaging modality, such as PET, SPECT, MRI, optical, and ultrasound. The advantages and disadvantages of each of these modalities are discussed in regard to spatial resolution, temporal resolution, sensitivity, and cost. Molecular imaging agents can be divided into three categories, Type A, which bind directly to a target molecule, Type B, which are accumulated by molecular or cellular activity by the target, and Type C, which are undetectable when injected but can be imaged after they are activated by the target. The current status of clinical molecular imaging agents is presented as well as examples of some preclinical applications. The value of molecular imaging is illustrated by some examples for diseases such as cancer, neurological and psychiatric disorders, cardiovascular disease, infection and inflammation, and the monitoring of gene therapy and stem cell therapy.

Current developments in SELDI affinity technology

The overall history and recent advancements in Surface-Enhanced Laser Desorption/Ionization (SELDI) affinity technology is reviewed. A detailed account of SELDI technology, utilizing Immobilized-Metal Affinity surfaces, pseudo-specific chromatographic surfaces, and biospecific interactive surfaces, is presented with particular emphasis placed upon examination of fundamental characteristics as well as specific applications for each. Finally, a detailed review of the specific use of such affinity surfaces in fundamental aspects of clinical, process, and research proteomics activity is presented.

Molecular imaging: looking at problems, seeing solutions

Noninvasive molecular-imaging technologies are providing researchers with exciting new opportunities to study small-animal models of human disease. With continued improvements in instrumentation, identification of better imaging targets by genome-based approaches, and design of better imaging probes by innovative chemistry, these technologies promise to play increasingly important roles in disease diagnosis and therapy.

[Molecular imaging]

The disclosure of the human genoma, the progress in understanding of diseases on molecular and cellular levels, the discovery of new disease-specific targets, and the development of new medications will revolutionize our understanding of the etiology and the treatment of many disease entities. Radiologists are faced with a paradigm shift from unspecific to specific molecular imaging techniques as well as with enormous speed in the development of new methods and should be enrolled actively in this field of medicine.

Biochips beyond DNA: technologies and applications

Technological advances in miniaturization have found a niche in biology and signal the beginning of a new revolution. Most of the attention and advances have been made with DNA chips yet a lot of progress is being made in the use of other biomolecules and cells. A variety of reviews have covered only different aspects and technologies but leading to the shared terminology of "biochips." This review provides a basic introduction and an in-depth survey of the different technologies and applications involving the use of non-DNA molecules such as proteins and cells. The review focuses on microarrays and microfluidics, but also describes some cellular systems (studies involving patterning and sensor chips) and nanotechnology. The principles of each technology including parameters involved in biochip design and operation are outlined. A discussion of the different biological and biomedical applications illustrates the significance of biochips in biotechnology.

[Tissue microarray technology--a new and powerful tool for the molecular profiling of tumors]

Tissue Microarrays (TMA) are the products of a new technology that offers rapid and simultaneous analysis of up to 1000 different archival samples. Sections from TMA blocks can be used for all different types of in situ tissue analysis including immunohistochemistry and in situ hybridization. The technology helps to implement the vast knowledge that was discovered by the human genome project and facilitates the molecular understanding of various benign and malignant processes. In this article we describe the process of TMA construction and review the main studies that applied the technology to characterizing tumors and precancerous lesions.

Chemical genetic screening approaches to neurobiology

Chemical genetics is an emerging technology for revealing the signaling networks that regulate biological phenotypes using exogenous reagents such as small organic molecules. To study neurobiology using chemical genetics, high-throughput cell and organismal assays can be created to identify compounds and proteins that regulate diverse neuronal phenotypes, such as cell viability, gene expression level, protein association, protein aggregation, glutamate uptake, membrane polarization, mitochondrial function, neurite outgrowth, and growth cone composition. This powerful set of tools will enable the molecular dissection of complex processes that occur within the nervous system.

Chemical genetics: a small molecule approach to neurobiology

Chemical genetics, or the specific modulation of cellular systems by small molecules, has complemented classical genetic analysis throughout the history of neurobiology. We outline several of its contributions to the understanding of ion channel biology, heat and cold signal transduction, sleep and diurnal rhythm regulation, effects of immunophilin ligands, and cell surface oligosaccharides with respect to neurobiology.

Molecular methods for diagnosis of infective endocarditis

The culture of viable microorganisms from the blood or from cardiac tissue is currently the most important test for diagnosis of IE. This is followed by phenotypic identification methods used for taxonomic positioning of isolates. However, in those cases where the invading microorganism is difficult or impossible to culture (including instances of prior antimicrobial treatment), molecular methods provide the best means for detection. Molecular identification methods, either nucleic acid target or signal amplification alone or in combination with sequence analysis can offer a more specific and in some cases a more rapid alternative to the phenotypic methods. We propose revised Duke criteria of IE, including positive identification of an organism by molecular biology methods.

Von Willebrand factor collagen-binding (activity) assay in the diagnosis of von Willebrand disease: a 15-year journey

The correct diagnosis and classification of von Willebrand disease (vWD) is crucial because the presenting biological activity of von Willebrand factor (vWF) determines both the hemorrhagic risk and the subsequent clinical management. A variety of laboratory assays may be employed, not necessarily restricted to assessments of vWF. This article discusses the relative strengths and limitations of various functional or discriminatory vWF assays with a special focus on the vWF:collagen-binding activity (vWF:CBA) assay. This is a functional vWF assay that relies on the property of vWF adhesion to collagen. The vWF:CBA was first described approximately 15 years ago. The journey from that time point has been an interesting one, and the vWF:CBA is now gaining more widespread acceptance. There are now many published studies confirming the superiority of the vWF:CBA over the vWF ristocetin cofactor (vWF:RCof) activity as a functional screening diagnostic test process for vWD. However, both tests may be required in order to appropriately diagnose all forms of vWD. The relationship of these assays with multimer analysis is also discussed. In summary, an optimized vWF:CBA detects primarily high-molecular-weight (HMW) vWF forms and probably only about 30% of the total plasma vWF pool detected by vWF antigen (vWF:Ag). Because these HMW vWF forms are missing in types 2A and 2B vWD, the vWF:CBA is extremely useful in the detection of these qualitative vWD subtypes. In addition, however, concordance of vWF:CBA with vWF:Ag in unison with low vWF levels may alternatively suggest a type 1 vWD, and an absence of both vWF:Ag and vWF:CBA will suggest type 3 vWD. The vWF:CBA is also being investigated in various disease states, as is its usefulness as an effective marker of functional HMW vWF in both desmopressin (DDAVP) and factor-concentrate therapy in vWD.

On brain lesions, the milkman and Sigmunda

Lesion studies have been of historical importance in establishing the brain systems involved in memory processes. Many of those studies, however, have been overinterpreted in terms of the actual role of each system and of connections between systems. The more recent molecular pharmacological approach has produced major advances in these two areas. The main biochemical steps of memory formation in the CAI region of the hippocampus have been established by localized microinfusions of drugs acting on specific enzymes of receptors, by subcellular measurements of the activity or function of those enzymes and receptors at definite times, and by transgenic deletions or changes of those proteins. The biochemical steps of long-term memory formation in CAI have been found to be quite similar to those of long-term potentiation in the same region, and of other forms of plasticity. Connections between the hippocampus and the entorhinal and parietal cortices in the formation and modulation of short- and long-term memory have also been elucidated using these techniques. Lesion studies, coupled with imaging studies, still have a role to play; with regard to human memory, this role is in many ways unique. But these methods by themselves are not informative as to the mechanisms of memory processing, storage or modulation.

The role of technology in the clinical laboratory of the future

Advances in automation and informatics will drive the implementation of new technology as we enter the 21st century. Five technologies which will have the greatest impact on the practice of laboratory medicine during the next decade include molecular diagnostics, near patient testing, image analysis, robotics, and information management. The list of molecular pathology tests with potential clinical utility expands daily. Some, such as tests for human immune deficiency virus (HIV) and hepatitis C virus, already are available as commercial kits. Quality assessment and proficiency testing programs still are evolving. DNA tests in oncology, such as T- and B-cell gene rearrangements and t(9;22) translocation, have proven useful in detecting small numbers of tumor cells and have demonstrated clinical utility in some circumstances. Tests for monogenetic diseases, such as sickle cell disease, are useful in planning antenatal management of mothers at risk. Screening tests for the genetic predisposition for certain forms of colon and breast cancer and Alzheimer's Disease are now possible. This suggests the potential for large scale screening of populations at risk. Continued improvements in biosensor technology and miniaturization will increase the ability to test for many analytes at or near the patient. The generally increased cost per test must be reconciled with the potential to decrease the overall cost of care by improved turnaround time. Computerized image analysis will radically change, and in some cases eliminate, manual clinical microscopy in urinalysis, hematology, immunohistochemistry, and cytology. Robotics will greatly decrease personnel requirements for repetitive tasks, such as specimen transport, processing, and aliquoting. We will process many specimens from start to finish without human intervention. Image management systems will allow archiving of diagnostic gross and microscopic images along with the traditional text descriptions and diagnosis. Telepathology will link smaller centers with expert consultants in tertiary centers. Voice recognition systems will obviate the need for transcriptionists. Modern database architectures will allow the clinical laboratory to measure performance effectiveness and clinical outcomes and will place laboratorians at the forefront of outcomes research. Hand-held devices will allow physicians to conveniently order laboratory tests and retrieve results, further decreasing the functional turnaround time for laboratory testing. All of these technologies will be expensive to implement, but well-planned deployment will both decrease cost and improve the quality of medical care.

PCR (polymerase chain reaction) and the future of molecular testing

Molecular testing is no longer exotic, distant, or complex. It's moving into your lab and revolutionizing the rapid diagnosis of pathogenic organisms as well as your role as a laboratorian.